← Leaderboards
John A Barranger
University Of Pittsburgh At Pittsburgh
$2,026,465
Attributed
$2,026,465
Total exposure
13
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,026,465 · 13
By mechanism
U01$1,461,850 · 1
P01$505,080 · 1
M01$59,535 · 9
P41$0 · 1
U54$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- John Barranger$6,068
- Robert D Nicholls$6,020,455
- P. David Adelson$10,558,251
- Michael T Lotze$5,139,928
- Johnny Huard$5,437,784
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectGlucosylceramidaseGaucher'S DiseaseGene TherapyEnzyme TherapyMetabolism Disorder ChemotherapyBiomedical FacilityTransfection /Expression VectorLongitudinal Human StudyPatient Oriented ResearchClinical Trial Phase ICooperative StudyBiotechnologySkeletal DisorderCell LineInjection /InfusionTransfectionDrug MetabolismCd34 MoleculeBone Marrow TransplantationAdeno Associated Virus GroupHematopoietic Stem Cells
Grant awards (32)
Treatment of Gaucher Disease Using Glucocerebrosidase$24,674
M01 · FY2004 · RR
A PH2 Rand OL Dose Ranging Multiple Dose Study Fabrazyme in Pts w/Fabry Disease$18,569
M01 · FY2004 · RR
Trtmt Fabry Disease Using Recomb. Galact. A$8,140
M01 · FY2004 · RR
Treatment of Gaucher Disease Using Glucocerebrosidase Infusion$7,010
M01 · FY2004 · RR
Multicenter Study--Cerezyme in Treating Skeletal Disease$763
M01 · FY2004 · RR
An Observational Study of Patients with Fabry Disease$379
M01 · FY2004 · RR
Core--AAV Vector Facility$0
U54 · FY2003 · AR
Core--Human gene therapy applications laboratory (HGTAL)$292,370
U01 · FY2002 · HL
Core--Human gene therapy applications laboratory (HGTAL)$292,370
U01 · FY2002 · HL
GLUCOCEREBROSIDASE GENE TRANSFER TO CD34 CELLS$0
M01 · FY2002 · RR
GLUCOCEREBROSIDASE GENE TRANSFER TO CD34 CELLS$0
M01 · FY2002 · RR
CEREZYME IN TREATING SKELETAL DISEASE IN GAUCHER DISEASE$0
M01 · FY2002 · RR
CEREZYME IN TREATING SKELETAL DISEASE IN GAUCHER DISEASE$0
M01 · FY2002 · RR
ENZYME THERAPY FOR NEUROLOGICALLY AFFECTED PATIENTS WITH GAUCHER DISEASE$0
M01 · FY2002 · RR
TREATMENT OF GAUCHER DISEASE USING GLUCOCEREBROSIDASE INFUSION$0
M01 · FY2002 · RR
MOLECULAR ANALYSIS OF GENETIC DISEASES OF METABOLISM$0
P41 · FY2002 · RR
MOLECULAR ANALYSIS OF GENETIC DISEASES OF METABOLISM$0
P41 · FY2002 · RR
Core--Human gene therapy applications laboratory (HGTAL)$292,370
U01 · FY2001 · HL
Core--Human gene therapy applications laboratory (HGTAL)$292,370
U01 · FY2001 · HL
CORE--HUMAN GENE THERAPY APPLICATION LABORATORY$168,360
P01 · FY2001 · CA
ENZYME THERAPY FOR NEUROLOGICALLY AFFECTED PATIENTS WITH GAUCHER DISEASE$0
M01 · FY2001 · RR
TREATMENT OF GAUCHER DISEASE USING GLUCOCEREBROSIDASE INFUSION$0
M01 · FY2001 · RR
CEREZYME IN TREATING SKELETAL DISEASE IN GAUCHER DISEASE$0
M01 · FY2001 · RR
GLUCOCEREBROSIDASE GENE TRANSFER TO CD34 CELLS$0
M01 · FY2001 · RR
MOLECULAR ANALYSIS OF GENETIC DISEASES OF METABOLISM$0
P41 · FY2001 · RR
Core--Human gene therapy applications laboratory (HGTAL)$292,370
U01 · FY2000 · HL
CORE--HUMAN GENE THERAPY APPLICATION LABORATORY$168,360
P01 · FY2000 · CA
CORE--HUMAN GENE THERAPY APPLICATION LABORATORY$168,360
P01 · FY2000 · CA
CEREZYME IN TREATING SKELETAL DISEASE IN GAUCHER DISEASE$0
M01 · FY2000 · RR
ENZYME THERAPY FOR NEUROLOGICALLY AFFECTED PATIENTS WITH GAUCHER DISEASE$0
M01 · FY2000 · RR
TREATMENT OF GAUCHER DISEASE USING GLUCOCEREBROSIDASE INFUSION$0
M01 · FY2000 · RR
GLUCOCEREBROSIDASE GENE TRANSFER TO CD34 CELLS$0
M01 · FY2000 · RR